

ORIGINAL ARTICLE

Anthrax toxin receptor 1/tumor endothelial marker 8 promotes gastric cancer progression through activation of the PI3K/AKT/mTOR signaling pathway

Chen Cai^{1,2} | Wei Dang^{1,2} | Shilei Liu^{1,2} | Ling Huang^{1,2} | Yang Li^{1,2} | Guoqiang Li^{1,2} | Siyuan Yan^{1,2} | Chengkai Jiang^{1,2} | Xiaoling Song^{1,2} | Yunping Hu^{1,2} | Jun Gu^{1,2}

¹Department of General Surgery, Xinhua Hospital Affiliated to Shanghai Jiaotong University School of Medicine, Shanghai, China

²Shanghai Key Laboratory of Biliary Tract Disease Research, Shanghai, China

Correspondence

Jun Gu, Department of General Surgery, Xinhua Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, Shanghai, China.
Email: gujun02@xinhumed.com.cn

Yunping Hu, Shanghai Key Laboratory of Biliary Tract Disease Research, Shanghai, China.
Email: kevintony@126.com

Funding information

National Natural Science Foundation of China, Grant/Award Number: 81572819

Abstract

Anthrax toxin receptor 1 (ANTXR1), a type I transmembrane protein, is one of the receptors that facilitates the entrance of anthrax toxin into cells. Previous studies have confirmed the pivotal role of ANTXR1 in progression and tumorigenesis of diverse cancer types. However, the biological function of ANTXR1 in gastric cancer (GC) is still unknown. The present study aimed to investigate the role of ANTXR1 in GC and illuminate the potential molecular mechanisms. Bioinformatics analysis found that ANTXR1 expression was significantly upregulated in GC tissue and its overexpression was associated with poor prognosis of GC patients. Moreover, we confirmed the upregulation of ANTXR1 in GC cell lines and GC tissue by quantitative PCR, western blot analysis, and immunohistochemical analysis. Additionally, high protein expression level of ANTXR1 was positively associated with several clinicopathological parameters in GC patients. In our study, a series of in vitro and in vivo assays were undertaken through strategies of loss/gain-of-function and rescue assays. Consequently, our results indicated that ANTXR1 induced proliferation, cell cycle progression, invasion and migration, and tumorigenicity and induced suppressed apoptosis in GC. Mechanistic investigation indicated that ANTXR1 exerted its promoting effects on GC through activation of the PI3K/AKT/mTOR signaling pathway. In conclusion, our findings suggested that ANTXR1 plays a crucial role in the development and progression of GC and could serve as a novel prognostic biomarker and potential therapeutic target for GC.

KEYWORDS

ANTXR1, EMT, gastric cancer, metastasis, proliferation

Abbreviations: ANTXR1, anthrax toxin receptor 1; EC, endothelial cell; EMT, epithelial-mesenchymal transition; GC, gastric cancer; IHC, immunohistochemistry; p-, phosphorylated; PI, propidium iodide; qPCR, quantitative PCR; SVV, Seneca Valley virus; TEM8, tumor endothelial marker 8.

Cai, Dang, and Liu contributed equally to this work.

This is an open access article under the terms of the Creative Commons Attribution-NonCommercial License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited and is not used for commercial purposes.

© 2020 The Authors. *Cancer Science* published by John Wiley & Sons Australia, Ltd on behalf of Japanese Cancer Association.

1 | INTRODUCTION

Gastric cancer is one of the most common malignancies of the digestive system, the fifth most frequently diagnosed cancer, and the third leading cause of cancer death.¹ The incidence rate of GC is markedly high in eastern Asia. The age-standardized 5-year net survival rate of patients with GC has been reported to be generally in the range 20%-40%.^{2,3} A majority of patients with GC are diagnosed with advanced stage or distant metastasis.⁴ Despite the development of techniques for the diagnosis and treatment of GC, prognosis for patients with advanced-stage GC is still discouraging.⁵⁻⁷ Therefore, there is an urgent need to clarify the mechanism involved in the process and metastasis of GC, which will help elucidate specific molecular targets and improve diagnosis and prognosis.

Anthrax toxin receptor 1, also known as ATR, GAPO, or TEM8, is a type I transmembrane protein, is encoded by the highly conserved *TEM8* gene.⁸ Tumor endothelial marker 8 is a highly conserved cell-surface glycoprotein that was originally identified by its overexpression in ECs that line the tumor vasculature of colorectal cancer.⁸ Several studies have shown that TEM8 binds to the C5 domain of collagen type VI and promotes migration of ECs in vitro.^{9,10} Furthermore, TEM8 plays a significant role in cell attachment and migration, and interacts with ECM proteins and the actin cytoskeleton. It also mediates adhesion of cells to type 1 collagen and gelatin, reorganization of the actin cytoskeleton, and promotes cell spreading.¹¹ Previous studies found that TEM8 is involved in the angiogenic response of cultured umbilical vein ECs by regulating cell-matrix interactions on collagen.¹² Originally, TEM8 was identified as one a cell surface receptor of anthrax toxin, so it was alternatively named ANTXR1.¹³ Recent studies identified ANTXR1 as the high-affinity cellular receptor for SVV.¹⁴ Seneca Valley virus has shown encouraging results and a favorable safety profile as an oncolytic virus in clinical trials, and this finding offers a promising biomarker for selecting patient response to treatment.^{11,15-17} The extracellular domains of ANTXR1 share homology with integrins, and interactions with collagen IV, collagen VI, and laminin suggest a possible function in basement membrane assembly and angiogenesis.^{18,19} In comparison with the wide distribution in normal tissue of ANTXR2, ANTXR1 is overexpressed in tumor cells and the vasculature of developing carcinoma.^{9,12} Previous studies reported that approximately 63% of cell lines surpass the expression cut-off line of ANTXR1 among 1037 cell lines in the Cancer Cell Line Encyclopedia.¹⁴

In the present study, we found that ANTXR1 plays a critical role in promoting GC progression. A series of in vitro and in vivo assays revealed that knockdown of ANTXR1 in GC cells dramatically suppressed cell proliferation, cell cycle progression, invasion and migration, and tumorigenicity and induced apoptosis, whereas overexpression of ANTXR1 had the opposite effect. Furthermore, our mechanistic investigations revealed that ANTXR1 induced GC cell proliferation and aggressiveness by activating the PI3K/AKT/mTOR signaling pathway. Our findings indicated that ANTXR1 plays a role as a novel oncogene in GC and could be a potential diagnostic and therapeutic target.

2 | MATERIALS AND METHODS

2.1 | Tissue specimens

Human GC tissue and adjacent nonmalignant tissue were obtained from the Department of General Surgery in Xinhua Hospital affiliated with Shanghai Jiao Tong University (Shanghai, China). None of the patients received radiotherapy or chemotherapy before surgery. All diagnostic information was gathered based on the American Joint Committee on Cancer (8th edition) guidelines. We obtained informed consent from all patients and the study was approved by the Research Ethics Committee of Xinhua Hospital, School of Medicine, Shanghai Jiao Tong University (approval no. XHEC-F-2019-029).

2.2 | Cell lines and reagents

The 4 human GC cell lines, BGC823, MGC803, HGC27, and SGC7901, and human gastric mucosal epithelial cell line (GES-1) were purchased from the cell bank of the Chinese Academy of Sciences (Shanghai, China). All cells were authenticated by short tandem repeat profiling and cultured in RPMI-1640 (Hyclone) containing 10% FBS (Gibco). These cell lines were incubated in a humidified incubator containing 5% CO₂ at 37°C.

LY294002 (Cat. No. 154447-36-6) was purchased from MedChemExpress and dissolved in DMSO. Both HGC27/ANTXR1 and SGC7901/ANTXR1 cells were treated with LY294002 for 48 hours at the recommended concentration of 20 μM.

2.3 | Total RNA extraction and qRT-PCR

Total RNA was extracted from the cells or tissue samples using TRIzol reagent (Invitrogen). The cDNA was synthesized using the PrimeScript RT reagent kit with gDNA Eraser (TaKaRa) according to the manufacturer's instructions. Quantitative real-time PCR was undertaken using SYBR Green (TaKaRa) according to the manufacturer's instructions.

Target genes were measured by using an Applied Biosystems StepOnePlus real-time thermocycler (Applied Biosystems). The specific primer sequences used to amplify ANTXR1 were: 5'-ACAGTTGGCTCACAATTCATCA-3' (forward) and 5'-TCACTGGCCCTTCAAATCCT-3' (reverse). GAPDH was used as an endogenous control in PCR analysis. Relative gene expression levels were quantified by the comparative 2^{-Ct} method and cycle thresholds were normalized to GAPDH levels.

2.4 | Western blot analysis

The protein was extracted by RIPA lysis buffer (Beyotime) containing cocktail protease inhibitors and cocktail phosphatase inhibitors. Protein quantification was undertaken using BCA assays (Beyotime).

Proteins from cell and tissue samples were separated by SDS-PAGE and electrotransferred onto PVDF membranes (Millipore). The PVDF membranes were blocked with 5% skimmed milk for 1 hour at room temperature. Subsequently, the bands were incubated with the following primary Abs including anti-ANTXR1 (1:1000, #A6525; ABclonal), anti-P-PI3K (1:1000, #4228; Cell Signaling Technology), anti-PI3K (1:1000, #4249; Cell Signaling Technology), anti-AKT (1:1000, #4691; Cell Signaling Technology), anti-P-AKT (1:1000, #4060; Cell Signaling Technology), anti-mTOR (1:1000, #2983; Cell Signaling Technology), anti-P-mTOR (1:1000, #5536; Cell Signaling Technology), anti-E-cadherin (1:1000, #3195; Cell Signaling Technology), anti-vimentin (1:1000, #5741; Cell Signaling Technology), anti-snail (1:1000, #3879; Cell Signaling Technology), anti-cleaved caspase 3 (1:1000, #9662; Cell Signaling Technology), anti-Bcl-2 (1:1000, #4223; Cell Signaling Technology), anti-cytochrome C (1:1000, #11940; Cell Signaling Technology), anti-cyclin D1 (1:1000, #2978; Cell Signaling Technology), anti-p21Cip1 (1:1000, #2947; Cell Signaling Technology), anti-p27Kip1 (1:1000, #3686; Cell Signaling Technology), and anti- β -tubulin (1:3000, #AB0039; Abways) at 4°C overnight. The next day, the membranes were incubated with a goat anti-rabbit HRP-conjugated secondary Ab (1:1000, #A0208; Beyotime). Western blot analyses were repeated 3 times independently.

2.5 | Cell transfection

Anthrax toxin receptor 1 was silenced in BGC823 and MGC803 cells with siRNA (Biotend) using Rfect transfection reagent (BAIDAI) according to the manufacturer's instructions using siRNA-ANTXR1-1 (sense, GGUGUGGUAAGAAACUCAAAdTdT; antisense, UUGAGUUUCUUACACACCCdTdT) and siRNA-ANTXR1-2 (sense, GCAACUACAGUCAGAUUUdTdT; antisense, UAAAUUCGACUGUAGUUGCdTdT).

Overexpression of ANTXR1 in HGC27 and SGC7901 cells was achieved by lentiviral infection. For ANTXR1 overexpression in GC cells, the ANTXR1 gene was synthesized according to the human ANTXR1 mRNA sequence and was constructed into a lentiviral expression vector; empty vector was used as the control (Shanghai Genechem). Control cells were transfected with empty vectors. Overexpression plasmids lentiviral vector carrying GFP was synthesized by GeneChem. Lentiviral infection was carried out according to the manufacturer's instructions. Stably transfected cell lines were selected for 2 weeks using puromycin (1 μ g/mL). The transfection efficiency in the infected cells was validated by western blotting, qRT-PCR, and fluorescence microscopy. The stable ANTXR1-overexpressing cell lines were named HGC27/ANTXR1 and SGC7901/ANTXR1.

2.6 | Cell proliferation assay

The CCK-8 assay (Yeasten) is used to evaluate the level of cell proliferation. Gastric cancer cells were seeded into 96-well plates at

the density of 1000 cells per well with 100 μ L complete medium. At each time point (6, 24, 48, 72, 96, and 120 hours), 10 μ L CCK-8 reagent was added to each well and incubated at 37°C. After 2 hours of incubation, we measured the optical density at 450 nm with a SpectraMax 190 Microplate Reader. Three independent experiments were carried out for the final results.

2.7 | Colony formation assay

Gastric cancer cells were seeded into 6-well plates at the density of 500 cells per well with 2.5 mL complete medium and cultured for 2 weeks. Two weeks later, colonies were fixed with 4% paraformaldehyde for 30 minutes and then stained with 0.5% crystal violet stain solution (Yeasten) for 30 minutes. The number of colonies containing more than 50 cells was counted.

2.8 | Invasion and migration assays

Gastric cancer cells were resuspended in 100 μ L serum-free medium and then seeded at a density of 6×10^4 HGC27 or BGC823 cells (8×10^4 SGC7901 and 3×10^4 MGC803 cells) into the upper chamber of an 8- μ m pore size (Corning) or BioCoat Matrigel Invasion Chamber (Corning). The lower compartments were put into a 24-well plate filled with 600 μ L medium containing 10% FBS. The plate was incubated for 24 hours in a humidified tissue culture incubator at 37°C in a 5% CO₂ atmosphere. After incubation, cells were fixed in 4% paraformaldehyde for 30 minutes and stained with 0.5% crystal violet stain solution (Yeasten) for 30 minutes. Cell numbers were counted in 5 random fields, and images were captured under a microscope at a magnification of 100 $\times$.

2.9 | Apoptosis assay

An annexin V-Alexa Fluor 647/PI Apoptosis Detection Kit (Cat No. 40304; Yeasen) was used to detect the apoptosis rate of GC cells according to the manufacturer's instructions. Briefly, GC cells were washed twice with cold PBS and then resuspended in 1 $\times$ binding buffer. Next, 5 μ L annexin V-Alexa Fluor 647 and 10 μ L PI staining solution were added into the binding buffer. After incubation for 15 minutes at room temperature in the dark, samples were analyzed by flow cytometry (BD Biosciences).

2.10 | Cell cycle assay

Cell Cycle Analysis Kit (Beyotime) was used to analyze the cell cycle distribution. Gastric cancer cells were harvested from 6-well plates and washed twice with cold PBS. Subsequently, the cells were fixed with 70% ethanol at 4°C overnight. The next day, the cells were treated with RNase A solution and stained with PI for 30 minutes at

37°C. The cell cycle distribution (G_0/G_1 , S and G_2/M) were measured by flow cytometry (BD Biosciences) and analyzed by ModFit software (BD Biosciences).

2.11 | Subcutaneous xenograft models

Male BALB/c nude mice (4 weeks old) were purchased from Shanghai SLRC Laboratory Animal Co. and maintained under specific pathogen-free conditions. One group contained 5 mice and each mouse was s.c. inoculated with 5×10^6 cells of SGC7901 with stable overexpression of ANT XR1 (SGC7901/ANT XR1) that had been resuspended in Matrigel (BD Biosciences). Tumor size was measured with calipers every 4 days, and the tumor volume was calculated using the following formula: $\pi/6 \times \text{length} \times \text{width}^2$. Four weeks after injection, the mice were killed, and the xenograft tumors were dissected for IHC assays. All animal studies were carried out with the approval of the Ethics Committee of Xinhua Hospital of the School of Medicine at Shanghai Jiaotong University (Approval No. XHEC-F-2019-029).

2.12 | Statistical analysis

All experiments were independently repeated 3 times, and quantitative data were expressed as mean $\pm$ SD. Prism 7 (GraphPad Software) and SPSS 24 (SPSS Inc.) were used for statistical analyses. The 2-tailed Student's *t* test was used to compare quantitative variables. The correlation between ANT XR1 expression and clinicopathological variables was calculated by Pearson's χ^2 test. Kaplan-Meier methods and log-rank tests were used for the survival analysis. *P* values less than .05 were considered statistically significant. Significant differences are indicated by asterisks referring to the following *P* values: **P* < .05, ***P* < .01, and ****P* < .001.

3 | RESULTS

3.1 | Expression of ANT XR1 is upregulated in human GC tissue and GC cell lines

Based on the Oncomine database, we discovered that ANT XR1 expression is significantly upregulated in GC tissue compared with normal tissue. As shown in Figure 1A, 4 cases of datasets found that ANT XR1 mRNA levels were dramatically higher in cancer tissue. To further confirm the results of the Oncomine database, we tested expression levels of ANT XR1 in GC cells by qRT-PCR and western blotting. The results showed that expression level of ANT XR1 in GC cell lines (BGC823, MGC803, HGC27, and SGC7901) was significantly higher than in human gastric mucosal epithelial cell line GES-1 (Figure 1B,C). In order to further determine the expression level of ANT XR1 in clinical samples of human GC tissue, western blotting was used in 12 pairs of randomly selected human GC tissue and paired adjacent normal tissue. As described in Figure 1D,

the expression of ANT XR1 in GC tissue was significantly higher than that in matched adjacent normal tissue. In addition, IHC was applied to examine the protein expression level of ANT XR1 in 103 GC tissues. The result showed 64.08% (66/103) in GC tissue, indicating a relatively higher level of ANT XR1 compared with 31.07% (32/103) in the matched adjacent normal tissue. In addition, we found that ANT XR1 protein was mainly located in the cytoplasm of benign and malignant epithelial cells (Figure 2A).

Taken together, these results suggest that ANT XR1 is remarkably elevated in GC tissue and GC cell lines.

3.2 | High ANT XR1 expression is associated with several clinicopathologic parameters and poor prognosis of GC patients

As summarized in Table 1, high protein expression level of ANT XR1 was positively associated with T stage (*P* = .001), lymph node metastasis (*P* = .002), and clinical stage (*P* < .001) in GC patients. However, there was no significant correlation between ANT XR1 expression and other clinicopathological parameters (*P* > .05).

We detected whether the mRNA expression of ANT XR1 was related to cancer stage in GC patients using the UALCAN database.²⁰ As shown in Figure 2B, the results indicated that patients with a more advanced stage of GC tended to have higher ANT XR1 expression levels of their GC tissue, except the stage III group. Patients in stage IV expressed the highest mRNA levels of ANT XR1 (*P* < .05). Moreover, the data shown in Figure 2C indicate that patients with higher pathological grade tumors expressed higher levels of ANT XR1 mRNA (*P* < .05). However, no statistical significance was found between the grade I group and the normal group; we assumed the limited sample size in the grade I group caused the result.

Simultaneously, we used Kaplan-Meier plotter (<http://kmplot.com/>) and OncoLnc (<http://www.oncolnc.org/>) to further detect the prognostic values of the mRNA expression of ANT XR1 in GC patients. The result by Kaplan-Meier plotter revealed that high ANT XR1 expression was significantly associated with a shorter OS for all patients with GC (hazard ratio = 1.7; 95% confidence interval, 1.43-2.02; *P* = 8e-10; Figure 2D). The results by OncoLnc also shows the same tendency (*P* = .0174, Figure 2E).

3.3 | Anthrax toxin receptor 1 promotes proliferation of GC cells


We undertook CCK-8 and colony formation assays to evaluate the role of ANT XR1 in GC progression. First, we investigated the mRNA and protein endogenous ANT XR1 levels in GC cell lines (BGC823, MGC803, HGC27, and SGC7901) and human gastric mucosal epithelial cells (GES-1). The ANT XR1 expression levels were higher in BGC823 and MGC803 cells than in HGC27 and SGC7901 cells (Figure 1B,C). Subsequently, we knocked down ANT XR1 in BGC823 and MGC803 cells and overexpressed ANT XR1 in HGC27

(A)

Comparison of ANTXR1 across 4 analyses


Overexpression

Median rank	P-Value	Gene
249.5	3.25E-5	ANTXR1




Legend

1. Diffuse gastric adenocarcinoma vs. normal
Chen gastric, Mol Biol Cell, 2003
2. Gastric intestinal type adenocarcinoma vs. normal
Chen gastric, Mol Biol Cell, 2003
3. Gastric mixed adenocarcinoma vs. normal
Chen gastric, Mol Biol Cell, 2003
4. Gastric mixed adenocarcinoma vs. normal
DErrico gastric, Eur J Cancer, 2009




The rank for a gene is the median rank for that gene across each of the analyses.
The p-Value for a gene is its p-Value for the median-ranked analysis.


Diffuse gastric adenocarcinoma vs. normal
P-value: 5.66E-6; Fold change: 2.456




Gastric mixed adenocarcinoma vs. normal
P-value: 5.75E-5; Fold change: 2.664



Gastric mixed adenocarcinoma vs. normal
P-value: 1.26E-4; Fold change: 3.700




Gastric intestinal type adenocarcinoma vs. normal
P-value: 1.64E-16; Fold change: 2.033



(B)



(C)



(D)




FIGURE 1 Anthrax toxin receptor 1 (ANTXR1) expression was increased in gastric cancer (GC) tissue and GC cell lines. A, 4 datasets showed statistically significant ANTXR1 mRNA overexpression (red) based on the Oncomine database. B, C, Relative expression of ANTXR1 protein and mRNA in human gastric mucosal epithelial cell line GES-1 and 4 GC cell lines (BGC823, MGC803, HGC27, and SGC7901) by western blotting and quantitative PCR. D, Expression of ANTXR1 protein in 12 pairs of randomly selected human GC tissue and paired adjacent normal tissue by western blotting




FIGURE 2 Anthrax toxin receptor 1 (ANTXR1) overexpression is correlated with poor prognosis in gastric cancer (GC). A, Representative images of ANTXR1 expression in GC tissue and paired adjacent normal tissue by immunohistochemistry. The 6 images on the left are different staining intensities in GC tissue. Far right images show adjacent normal tissue. B, Expression level of ANTXR1 based on individual GC stages in the UALCAN database. C, Expression level of ANTXR1 based on GC tumor grade in the UALCAN database. D, E, Kaplan-Meier curves of overall survival in GC patients stratified by ANTXR1 expression. Patients with higher ANTXR1 expression had poorer prognosis. * $P < .05$, ** $P < .01$, *** $P < .001$. ns, non-significant

and SGC7901 cells to undertake loss-of-function and gain-of-function assays. To avoid off-target effects by siRNA, we constructed ANTXR1-knockdown cells using 2 ANTXR1-specific siRNAs.

Western blotting and qPCR analysis confirmed a significant decrease of ANTXR1 expression in BGC823 and MGC803 cells compared with the expression level of ANTXR1 in respective control

TABLE 1 Association of anthrax toxin receptor 1 (ANTXR1) expression with clinicopathologic parameters of gastric cancer (GC) patients

Characteristics	Total (n = 103)	ANTXR1 protein expression		P value
		Low (n = 37)	High (n = 66)	
Age (y)				
≤60	46	15	31	.529
>60	57	22	35	
Gender				
Male	63	20	43	.268
Female	40	17	23	
Differentiation				
Well + moderate	41	18	23	.170
Poor	62	19	43	
T classification				
T1 + T2	32	19	13	.001
T3 + T4	71	18	53	
Lymph node metastasis				
N0	38	21	17	.002
N1-3	65	16	49	
Distant metastasis				
M0	82	33	49	.071
M1	21	4	17	
AJCC stage				
I + II	35	23	12	<.001
III + IV	68	14	54	

Note: Results showed 64.08% (66/103) in GC tissue indicated a relatively higher level of ANTXR1 compared with 31.07% (32/103) in the matched adjacent normal tissue. AJCC, American Joint Committee on Cancer.

cells (Figure 3A,B). The CCK8 and colony formation assays showed that GC cell proliferation abilities were significantly inhibited after downregulation of ANTXR1 (Figure 3C,D). Simultaneously, 2 stable ANTXR1-overexpressed GC cell lines, HGC27/ANTXR1 and SGC7901/ANTXR1, were established (Figure 4A,B). As expected, the CCK-8 and colony formation assays showed that GC cell proliferation abilities were remarkably enhanced after upregulation of ANTXR1 (Figure 4C,D).

3.4 | Anthrax toxin receptor 1 promotes GC cell migration and invasion in vitro through EMT

To explore whether ANTXR1 expression levels affect GC metastasis, we undertook Transwell migration and Matrigel cell invasion assays. As shown in Figure 3E, downregulation of ANTXR1 remarkably repressed the migratory and invasive abilities of BGC823 and MGC803 cells. In contrast, overexpression of ANTXR1 remarkably enhanced the migratory and invasive abilities of HGC27 and SGC7901 cells (Figure 4E). Collectively, these results showed that ANTXR1 affects GC cell migration and invasion in vitro.

Furthermore, we assuming that ANTXR1 might be involved in EMT of GC cells, a pivotal process characterized by tumor cell

migration and invasion. We detected the expression of EMT-associated markers by western blotting and found that downregulation of ANTXR1 in BGC823 and MGC803 cells upregulated epithelial marker E-cadherin, whereas mesenchymal markers Vimentin and EMT-associated transcription factor Snail were downregulated (Figure 3F). By contrast, E-cadherin was significantly decreased in ANTXR1-overexpressed cells (HGC27/ANTXR1 and SGC7901/ANTXR1) cells, whereas Vimentin and Snail were increased (Figure 4F). Therefore, we concluded that ANTXR1 could promote GC cell migration and invasion in vitro through EMT.

3.5 | Anthrax toxin receptor 1 accelerates cell-cycle G₁-S transition in GC cells

To investigate the possible mechanism of ANTXR1 in GC progression, we undertook flow cytometry analysis. The result suggested that silencing ANTXR1 increased the percentage of G₀/G₁ phase cells and reduced S phase cells, whereas overexpressing ANTXR1 significantly decreased the percentage of G₀/G₁ phase cells and increased the proportion of S phase cells (Figure 5A,B). In summary, our data indicated that ANTXR1 accelerates the GC cell cycle and furthers promote the proliferation of GC cells.




FIGURE 3 Downregulation of anthrax toxin receptor 1 (ANTXR1) inhibits proliferation, migration, and invasion of gastric cancer (GC) cells. A, B, Knockdown of ANT XR1 was confirmed at the protein and mRNA level in BGC823 and MGC803 cells by western blotting and quantitative PCR. C, D, ANT XR1 knockdown inhibited proliferation of BGC823 and MGC803 cells as determined by CCK-8 and colony formation assays. E, Transwell assays were undertaken to measure the effects of ANT XR1 downregulation on migration and invasion abilities of BGC823 and MGC803 cells. F, Western blot analysis of E-cadherin, Vimentin, and snail levels in GC cells transfected with ANT XR1-specific siRNA or control siRNA. * $P < .05$, ** $P < .01$, *** $P < .001$. NC, negative control

We further used western blotting analysis to explore whether ANT XR1 could adjust expressions of cell cycle-related proteins, including cyclin D1, p21Cip1, and p27Kip1. As shown in Figure 5C,D,

a significant decline of cyclin D1 was observed in ANT XR1-silenced GC cells compared to control groups, whereas p21Cip1 and p27Kip1 increased. On the contrary, a significant downregulation of p21Cip1




FIGURE 4 Overexpression of anthrax toxin receptor 1 (ANTXR1) promotes proliferation, migration, and invasion of gastric cancer (GC) cells. A, B, Overexpression (OE) of ANTXR1 was confirmed at the protein and mRNA level in HGC27 and SGC7901 cells by western blotting and quantitative PCR. C, D, Proliferation ability of ANTXR1 overexpression GC cells (HGC27/ANTXR1 and SGC7901/ANTXR1) without or with the PI3K inhibitor LY294002 (20 μ M, 48 h) was determined by CCK-8 and colony formation assays. E, Transwell assays were undertaken to measure the effects of ANTXR1 overexpression and LY294002 treatment on migration and invasion abilities of HGC27 and SGC7901 cells. F, Western blot analyses were used to measure the effects of ANTXR1 overexpression and LY294002 treatment on E-cadherin, Vimentin, and snail levels. * $P < .05$, ** $P < .01$, *** $P < .001$

and p27Kip1 was observed in ANTXR1-overexpressed GC cells compared to control groups, whereas cyclin D1 was remarkably upregulated. Taken together, our results show that ANTXR1 accelerated cell-cycle G_1 -S transition through regulating expression of cyclin D1, p21Cip1, and p27Kip1.

3.6 | Anthrax toxin receptor 1 inhibits apoptosis of gastric cancer cells

We used the annexin V-Alexa Fluor 647/PI Apoptosis Detection Kit to evaluate the effects of ANTXR1 on GC cell apoptosis by




FIGURE 5 Anthrax toxin receptor 1 (ANTXR1) inhibits apoptosis of gastric cancer (GC) cells and accelerated cell cycle G_1 -S transition in GC cells. A, B, Cell cycle distribution in different phases was analyzed by flow cytometry. C, D, Western blot analysis of cyclin D1, p21Cip1, and p27Kip1 in ANTXR1-silenced cells, ANTXR1-overexpressed (OE) cells, and ANTXR1-overexpressed cells treated with LY294002. E, F, Cells were stained with annexin V-Alexa Fluor 647/propidium iodide then apoptosis rates were assessed by flow cytometry. G, H, Western blot analysis of Bcl-2, cleaved caspase 3, and Cytochrome C in ANTXR1-silenced cells, ANTXR1-overexpressed cells, and ANTXR1-overexpressed cells treated with LY294002. * $P < .05$, ** $P < .01$, *** $P < .001$

flow cytometry. The results showed that the proportions of apoptotic cells in the ANTXR1-overexpressed HGC27 and SGC7901 cells were lower than those in the control groups, whereas the

ANTXR1-silenced BGC823 and MGC803 cells have more apoptotic cells than the control groups (Figure 5E,F). To investigate the molecular mechanism underlying the cell apoptosis caused by ANTXR1,

we evaluated the expression of apoptosis markers cleaved caspase-3 and cytochrome C, and survival-associated protein BCL-2. The protein expression levels of cleaved caspase-3 and cytochrome C were upregulated in ANT XR1-silenced BGC823 and MGC803 cells but downregulated in both HGC27/ANT XR1 and SGC7901/ANT XR1 cells. In addition, the protein expression levels of BCL-2 showed the opposite tendency (Figure 5G,H). Collectively, our data indicate that ANT XR1 could inhibit apoptosis of GC cells.

3.7 | Anthrax toxin receptor 1 promotes tumorigenesis of GC cells

To investigate the biological function of ANT XR1 on GC tumor growth *in vivo*, we undertook xenograft growth assays in nude mice by s.c. injection of SGC7901/ANT XR1 cells or negative control cells. As shown in Figure 6A,B, SGC7901/ANT XR1 cells had a significantly enhanced ability to form s.c. tumor nodules in nude mice compared to negative control cells, as indicated by the xenograft tumor volume, weight, and tumor growth curves (Figure 6C,D). The tumor sizes in 2 groups reached 100 mm³ at the first week, when we started to measure and record. Moreover, IHC staining showed that the proliferation index Ki-67 was higher in ANT XR1-overexpressed cells derived from tumor nodules than those derived from negative control cells. In addition, expression of EMT markers, including E-cadherin, N-cadherin, and vinculin, were significantly changed between the 2 groups. Expression of E-cadherin and vinculin were lower in the ANT XR1-overexpressed group; conversely, expression of N-cadherin was higher in the ANT XR1-overexpressed group (Figure 6E). Taken together, these results indicate that ANT XR1 plays a crucial role in the tumorigenesis of GC cells *in vivo*.

3.8 | Anthrax toxin receptor 1 promoted GC progression through the PI3K/AKT/mTOR signaling pathway

The PI3K/AKT/mTOR pathway plays a vital role in cancer cell transcription, translation, proliferation, survival and metastasis.²² A previous study suggested that ANT XR1 might have correlation with the PI3K/AKT pathway, by bioinformatics analysis.²³ Therefore, we further explored whether the oncogenic effects of ANT XR1 were dependent on the PI3K/AKT/mTOR signaling pathway. As shown in Figure 6F,G, p-PI3K, p-AKT, and p-mTOR were increased in ANT XR1-overexpressed groups but decreased in ANT XR1-silenced groups. To confirm these results, we used the PI3K inhibitor LY294002 to treat ANT XR1-overexpressed GC cells (HGC27/ANT XR1 and SGC7901/ANT XR1). We found that LY294002 treatment significantly downregulated the promotional effects on the expression levels of p-PI3K, p-AKT, and p-mTOR caused by ANT XR1 overexpression (Figure 6F,G). We also observed that the expression levels of the total PI3K, AKT, and mTOR showed no significant changes. Furthermore, we undertook rescue experiments to confirm that

ANT XR1 promoted GC progression through the PI3K/AKT/mTOR signaling pathway. The CCK-8 and colony formation assays revealed that LY294002 can dramatically suppress the proliferation ability of these ANT XR1-overexpressed cells (Figure 4C,D). We also investigated whether LY294002 could inhibit the promotional effects on migration and invasion, G₁-S transition, or promote the inhibitory effect on cell apoptosis caused by ANT XR1 overexpression. We found that LY294002 treatment induced suppression of cell migration and invasion and G₁-S transition, along with promotion of cell apoptosis in ANT XR1-overexpressed GC cells (Figures 4E and 5C,G).

4 | DISCUSSION

The results of the current study indicated that expression of ANT XR1 was extensively upregulated in GC tissue and GC cell lines. Immunohistochemistry indicated an association between ANT XR1 expression and several clinicopathological characteristics of 103 patients with GC. Kaplan-Meier analysis showed that high expression of ANT XR1 was positively correlated with poor survival in GC patients. Thus, we hypothesize that ANT XR1 contributes to supporting growth of GC and driving tumor cell invasion and metastatic dissemination.

Subsequently, we undertook a series of *in vitro* and *in vivo* assays to investigate the effects of ANT XR1 on GC cell growth. Our results indicated that knockdown of ANT XR1 suppressed GC cell proliferation, colony formation, migration, invasion, and tumorigenicity, and induced cell apoptosis and cell cycle arrest, whereas overexpression of ANT XR1 induced the opposite phenotype. Therefore, our findings provide further support for the hypothesis that ANT XR1 plays a vital role in the progression of GC and could be a novel diagnostic and therapeutic target.

Anthrax toxin receptor 1, a 564 amino acid type I transmembrane protein, is known as one of the receptors that facilitate the entrance of anthrax toxin into cells.¹³ Also known as TEM8, ANT XR1 specifically interacts with the protective antigen component of anthrax toxin and was originally identified by its overexpression in the endothelial cells that line the tumor vasculature of colorectal cancer.^{8,24} Moreover, ANT XR1 has previously been found to be specifically expressed in the tumor microenvironment.²⁵ In the context of cancer, ANT XR1 is upregulated in diverse cancer types and plays an important role in tumor development, such as lung cancer, breast cancer, and gallbladder carcinoma.²⁶⁻³¹ In addition, Shukla et al observed that ANT XR1 was expressed in 10.4% of T2 tumors, 79.5% of T3 tumors, and 84.8% of T4 tumors.²⁷ Additional studies were completed with breast tumors and normal tumor tissue and showed similar results.^{32,33} In the light of these previous reports, patients with ANT XR1 overexpression showed poor differentiation, advanced TNM stage, and significantly poorer prognosis. Prior to this work, Tuupanen and colleagues identified ANT XR1 as 1 of 33 candidate oncogenes by screening for base-specific mutations.³⁴ In addition, they also found that ANT XR1 is the most frequent target for hotspot mutations in a




FIGURE 6 Anthrax toxin receptor 1 (ANTXR1) promotes the tumorigenesis of gastric cancer (GC) cells and promotes GC progression through activation of the PI3K/AKT/mTOR signaling pathway. A, B, Overexpression (OE) of ANTXR1 promoted tumor growth in the nude mouse model by xenograft growth assay. C, D, Tumor weights and tumor volumes in the empty vector control group and the ANTXR1-overexpressed group. E, H&E staining and immunohistochemistry for ANTXR1, Ki67, E-cadherin, N-cadherin, and Vinculin in the empty vector control group and the ANTXR1-overexpressed group. F, G, Western blot analysis of phosphorylated (p-)PI3K, PI3K, p-AKT, AKT, p-mTOR, and mTOR expression in ANTXR1-silenced cells, ANTXR1-overexpressed cells, and ANTXR1-overexpressed cells treated with LY294002. * $P < .05$, ** $P < .01$, *** $P < .001$

validation set. In early 2018, researchers had obtained promising results when they applied ANT XR1 as a target of CAR T cell therapy in the preclinical phase of triple-negative breast cancer.³⁵ Subsequently, another study reported that ANT XR1 is the potent antigenic target for CAR T cell therapy of GC.³⁶ Taken together, it is a logical hypothesis that ANT XR1 might be involved in GC progression and metastasis. To the best of our knowledge, this is the first study to determine the biological function of ANT XR1 in GC and the correlation between expression of ANT XR1 and clinicopathological features of GC.

The PI3K/AKT/mTOR pathway is a classical signaling pathway playing a vital role in regulating cell growth, apoptosis, cell cycle, metastasis, and other cell biology processes in various cancer types, including GC.^{37–40} Once active, AKT regulates cell proliferation and tumor progression by phosphorylating a variety of downstream cell cycle-related and antiapoptotic proteins as well as transcription factors.⁴¹ Additionally, relevant studies have shown that the PI3K/AKT/mTOR pathway is activated in GC and GC patients with simultaneous expression of PI3K/AKT/mTOR had worse prognosis.^{42,43} A bioinformatics study²³ found that *ANT XR1*, as a differentially expressed gene, was associated with relapse-free survival and overall survival in GC and a Kyoto Encyclopedia of Genes and Genomes pathway analysis found that the PI3K-AKT signaling pathway was a significantly represented enriched pathway. To explore the regulation of molecular mechanisms of ANT XR1 for GC cell proliferation, cell cycle progression, invasion, and migration, we focused on the expression levels of proteins within the PI3K/AKT/mTOR pathway. In the present study, western blot analysis indicated that the expression levels of p-PI3K, p-AKT, and p-mTOR were significantly decreased by knockdown of ANT XR1 in both BGC823 and MGC803 cells. Likewise, western blot analysis showed that the expression levels of p-PI3K, p-AKT, and p-mTOR in the ANT XR1 overexpression group were significantly elevated, but not total AKT or mTOR, indicating that the PI3K/AKT/mTOR pathway might be involved in the molecular mechanism of ANT XR1 for GC progression. Moreover, our results showed that PI3K inhibitor LY294002 inhibits the function induced by overexpressed ANT XR1 in GC cells and reduced expression levels of p-PI3K, p-AKT, and p-mTOR in the ANT XR1-overexpression group. The above results contribute to establish a mechanistic rationale for validating our initial hypothesis that ANT XR1 promotes GC progression through the PI3K/AKT/mTOR signaling pathway.

In conclusion, our study showed that expression of ANT XR1 in GC tissue is significantly upregulated and closely associated with poor prognosis of GC patients. Additionally, our results suggested that ANT XR1 plays a critical role in promoting GC cell progression and invasiveness by activating the PI3K/AKT/mTOR signaling pathway. Our findings indicated that ANT XR1 could be a potential diagnostic and therapeutic target for GC.

ACKNOWLEDGMENTS

This study was supported by the National Natural Science Foundation of China (No. 81572819).

DISCLOSURE

The authors have declared that no competing interest exists.

ORCID

Chen Cai  <https://orcid.org/0000-0001-6742-0091>
Shilei Liu  <https://orcid.org/0000-0003-1700-4385>

REFERENCES

- Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. *CA Cancer J Clin*. 2018;68(6):394–424.
- Allemani C, Matsuda T, Di Carlo V, et al. Global surveillance of trends in cancer survival 2000–14 (CONCORD-3): analysis of individual records for 37 513 025 patients diagnosed with one of 18 cancers from 322 population-based registries in 71 countries. *Lancet*. 2018;391(10125):1023–1075.
- Sitarz R, Skierucha M, Mielko J, Offerhaus GJA, Maciejewski R, Polkowski WP. Gastric cancer: epidemiology, prevention, classification, and treatment. *Cancer Manag Res*. 2018;10:239–248.
- Van Cutsem E, Sagaert X, Topal B, Haustermans K, Prenen H. Gastric cancer. *Lancet*. 2016;388(10060):2654–2664.
- Catalano V, Labianca R, Beretta GD, Gatta G, de Braud F, Van Cutsem E. Gastric cancer. *Crit Rev Oncol Hematol*. 2009;71(2):127–164.
- Siegel RL, Miller KD, Jemal A. Cancer statistics, 2019. *CA Cancer J Clin*. 2019;69(1):7–34.
- Miller KD, Nogueira L, Mariotto AB, et al. Cancer treatment and survivorship statistics, 2019. *CA Cancer J Clin*. 2019;69:363–385.
- St Croix B, Rago C, Velculescu V, et al. Genes expressed in human tumor endothelium. *Science*. 2000;289(5482):1197–1202.
- Nanda A, Carson-Walter EB, Seaman S, et al. TEM8 interacts with the cleaved C5 domain of collagen alpha 3(VI). *Cancer Res*. 2004;64(3):817–820.
- Werner E, Kowalczyk AP, Faundez V. Anthrax toxin receptor 1/ tumor endothelium marker 8 mediates cell spreading by coupling extracellular ligands to the actin cytoskeleton. *J Biol Chem*. 2006;281(32):23227–23236.
- Burke MJ, Ahern C, Weigel BJ, et al. Phase I trial of Seneca Valley Virus (NTX-010) in children with relapsed/refractory solid tumors: a report of the Children's Oncology Group. *Pediatr Blood Cancer*. 2015;62(5):743–750.
- Hotchkiss KA, Basile CM, Spring SC, Bonuccelli G, Lisanti MP, Terman BI. TEM8 expression stimulates endothelial cell adhesion and migration by regulating cell-matrix interactions on collagen. *Exp Cell Res*. 2005;305(1):133–144.
- Bradley KA, Mogridge J, Mourez M, Collier RJ, Young JA. Identification of the cellular receptor for anthrax toxin. *Nature*. 2001;414(6860):225–229.
- Miles LA, Burga LN, Gardner EE, Bostina M, Poirier JT, Rudin CM. Anthrax toxin receptor 1 is the cellular receptor for Seneca Valley virus. *J Clin Invest*. 2017;127(8):2957–2967.
- Rudin CM, Poirier JT, Senzer NN, et al. Phase I clinical study of Seneca Valley Virus (SVV-001), a replication-competent picornavirus, in advanced solid tumors with neuroendocrine features. *Clin Cancer Res*. 2011;17(4):888–895.
- Burke MJ. Oncolytic Seneca Valley Virus: past perspectives and future directions. *Oncolytic Virother*. 2016;5:81–89.
- Reddy PS, Burroughs KD, Hales LM, et al. Seneca Valley virus, a systemically deliverable oncolytic picornavirus, and the treatment of neuroendocrine cancers. *J Natl Cancer Inst*. 2007;99(21):1623–1633.
- Bell SE, Mavila A, Salazar R, et al. Differential gene expression during capillary morphogenesis in 3D collagen matrices: regulated expression of genes involved in basement membrane matrix assembly, cell

- cycle progression, cellular differentiation and G-protein signaling. *J Cell Sci.* 2001;114(Pt 15):2755-2773.
19. Burgi J, Kunz B, Abrami L, et al. CMG2/ANTXR2 regulates extracellular collagen VI which accumulates in hyaline fibromatosis syndrome. *Nat Commun.* 2017;8:15861.
 20. Chandrashekar DS, Bashel B, Balasubramanya SAH, et al. UALCAN: a portal for facilitating tumor subgroup gene expression and survival analyses. *Neoplasia.* 2017;19(8):649-658.
 21. Nagy A, Lanczky A, Menyhart O, Gyorffy B. Validation of miRNA prognostic power in hepatocellular carcinoma using expression data of independent datasets. *Sci Rep.* 2018;8(1):9227.
 22. West KA, Castillo SS, Dennis PA. Activation of the PI3K/AKT pathway and chemotherapeutic resistance. *Drug Resist Updat.* 2002;5(6):234-248.
 23. Liu JB, Jian T, Yue C, et al. Chemo-resistant gastric cancer associated gene expression signature: bioinformatics analysis based on gene expression omnibus. *Anticancer Res.* 2019;39(4):1689-1698.
 24. Martchenko M, Jeong SY, Cohen SN. Heterodimeric integrin complexes containing beta1-integrin promote internalization and lethality of anthrax toxin. *Proc Natl Acad Sci USA.* 2010;107(35):15583-15588.
 25. Finak G, Bertos N, Pepin F, et al. Stromal gene expression predicts clinical outcome in breast cancer. *Nat Med.* 2008;14(5):518-527.
 26. Chen D, Bhat-Nakshatri P, Goswami C, Badve S, Nakshatri H. ANTXR1, a stem cell-enriched functional biomarker, connects collagen signaling to cancer stem-like cells and metastasis in breast cancer. *Cancer Res.* 2013;73(18):5821-5833.
 27. Maurya SK, Tewari M, Kumar M, Thakur MK, Shukla HS. Expression pattern of tumor endothelial marker 8 protein in gallbladder carcinomas. *Asian Pac J Cancer Prev.* 2011;12(2):507-512.
 28. Gong Q, Liu C, Wang C, Zhuang L, Zhang L, Wang X. Effect of silencing TEM8 gene on proliferation, apoptosis, migration and invasion of XWLC05 lung cancer cells. *Mol Med Rep.* 2018;17(1):911-917.
 29. Cao C, Wang Z, Huang L, et al. Down-regulation of tumor endothelial marker 8 suppresses cell proliferation mediated by ERK1/2 activity. *Sci Rep.* 2016;6:23419.
 30. Alcala S, Martinelli P, Hermann PC, Heeschen C, Sainz B Jr. The Anthrax Toxin Receptor 1 (ANTXR1) is enriched in pancreatic cancer stem cells derived from primary tumor cultures. *Stem Cells Int.* 2019;2019:1378639.
 31. Cullen M, Seaman S, Chaudhary A, et al. Host-derived tumor endothelial marker 8 promotes the growth of melanoma. *Cancer Res.* 2009;69(15):6021-6026.
 32. Davies G, Cunliffe GH, Mansel RE, Mason MD, Jiang WG. Levels of expression of endothelial markers specific to tumour-associated endothelial cells and their correlation with prognosis in patients with breast cancer. *Clin Exp Metastasis.* 2004;21(1):31-37.
 33. Davies G, Rmali KA, Watkins G, Mansel RE, Mason MD, Jiang WG. Elevated levels of tumour endothelial marker-8 in human breast cancer and its clinical significance. *Int J Oncol.* 2006;29(5):1311-1317.
 34. Tuupanen S, Hanninen UA, Kondelin J, et al. Identification of 33 candidate oncogenes by screening for base-specific mutations. *Br J Cancer.* 2014;111(8):1657-1662.
 35. Byrd TT, Fousek K, Pignata A, et al. TEM8/ANTXR1-specific CAR T cells as a targeted therapy for triple-negative breast cancer. *Cancer Res.* 2018;78(2):489-500.
 36. Sotoudeh M, Shirvani SI, Merat S, Ahmadbeigi N, Naderi M. MSLN (Mesothelin), ANTXR1 (TEM8), and MUC3A are the potent antigenic targets for CAR T cell therapy of gastric adenocarcinoma. *J Cell Biochem.* 2019;120(4):5010-5017.
 37. Ediriweera MK, Tennekoon KH, Samarakoon SR. Role of the PI3K/AKT/mTOR signaling pathway in ovarian cancer: Biological and therapeutic significance. *Semin Cancer Biol.* 2019;59:147-160.
 38. Corti F, Nichetti F, Raimondi A, et al. Targeting the PI3K/AKT/mTOR pathway in biliary tract cancers: a review of current evidences and future perspectives. *Cancer Treat Rev.* 2019;72:45-55.
 39. Sathe A, Nawroth R. Targeting the PI3K/AKT/mTOR pathway in bladder cancer. *Methods Mol Biol.* 2018;1655:335-350.
 40. Xing X, Zhang L, Wen X, et al. PP242 suppresses cell proliferation, metastasis, and angiogenesis of gastric cancer through inhibition of the PI3K/AKT/mTOR pathway. *Anticancer Drugs.* 2014;25(10):1129-1140.
 41. Manning BD, Toker A. AKT/PKB signaling: navigating the network. *Cell.* 2017;169(3):381-405.
 42. Ying J, Xu Q, Liu B, Zhang G, Chen L, Pan H. The expression of the PI3K/AKT/mTOR pathway in gastric cancer and its role in gastric cancer prognosis. *Oncotargets Ther.* 2015;8:2427-2433.
 43. Tapia O, Riquelme I, Leal P, et al. The PI3K/AKT/mTOR pathway is activated in gastric cancer with potential prognostic and predictive significance. *Virchows Arch.* 2014;465(1):25-33.

How to cite this article: Cai C, Dang W, Liu S, et al. Anthrax toxin receptor 1/tumor endothelial marker 8 promotes gastric cancer progression through activation of the PI3K/AKT/mTOR signaling pathway. *Cancer Sci.* 2020;00:1-14. <https://doi.org/10.1111/cas.14326>